Ann Roberts Brice



Ann Roberts Brice









As contributing writer, Ann currently covers the pharmaceutical and biotech industries for Life Science Leader, New Jersey Business and other magazines. Recent feature articles that she wrote include: Combating Counterfeit Drugs: A Global Dilemma Gaining An Edge in R&D — Johnson & Johnson Insights A Challenging Year for Biopharma — Issues and Trends NJ Medical Pro’s Help Men Live Longer, More Productive Lives NJ Hospitals Compete for Nurses—Use Job Benefits as Remedy Medical Advances Brighten Outlook for Cancer Patients During the past few years, she wrote profiles of several emerging biotech firms for Start-Up Magazine. Other stories include: “NJ Stem Cell Plan Thrown Out” — Nature Biotech, “New FDAAA Law: A Missed Opportunity” — BioWorld Perspectives and “Team Effort in Compliance Training” — Pharmaceutical Executive. The Garden State Journalists Association presented Ann with its Health and Science Award in 2007 for her behind-the-scenes feature article about clinical trials in NJ. A 230-page syndicated report that Ann wrote, US Cholesterol-Lowering Drugs 2005: Rx Market Analysis, was published by an international market research consulting firm. She also updated its market study, 2008 Global Outlook for Specialty Excipients. For seven years prior, Ann wrote news stories on US health care policies, company financial results and scientific news as US Reporter at Scrip World Pharmaceutical News in New York City. Scrip, the weekly newsletter and daily online service, is based in the UK. Previously, she contributed regularly to newsletters owned by the Financial Times. Ann earned a Bachelor’s Degree in Business and Education at Montclair State University and a Master’s Degree in Communications at New York University.


Feature articles and news stories on the business of pharmaceuticals and biotechnology. Topics include: evolving US health care policies. FDA prescription drug approvals and withdrawals. Generic drugs and biosimilars. OTC switch products and dietary supplements. Company R&D pipelines and clinical trials. Industry lawsuits. Medical research breakthroughs. Company financial results. Profiles of emerging biotech firms.

Member since: